MedTrace Logo

A Viveve Experience Normalizes Untreated Selective Serotonin Reuptake Inhibitor (SSRI) Sexuality Syndrome

NCT03679702 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2018-11-21

No results posted yet for this study

Summary

A pilot study to investigate non-surgical treatment for women who suffer from sexual complaints secondary to SSRI Sexuality Syndrome.

Conditions

  • Sexual Dysfunction

Interventions

DEVICE

Viveve System

Radiofrequency device utilized in general surgical procedures for electrocoagulation and hemostasis.

Sponsors & Collaborators

  • Viveve Inc.

    collaborator INDUSTRY

  • Michael Krychman, MD

    lead OTHER

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-12-15
Primary Completion
2019-12-01
Completion
2019-12-01
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03679702 on ClinicalTrials.gov